Synthesis and Chemical Biology
Alison is a Senior Lecturer in the School of Chemistry, a Fellow of the Royal Society of Chemistry and President of the Organic Division Council of the Royal Society of Chemistry (2016-19). Her research focuses on the synthesis and chemical biology/ medicinal chemistry applications of natural products. Past and current targets for her group include the pyrrolidine antibiotic anisomycin which activates the stress kinase pathways, a known cancer therapeutic target; the marine natural product bisebromoamide which has been shown to induce apoptosis through ERK and mTOR inhibition in renal cancer cells; and disorazole C1 which binds to tubulin at a site which is orthogonal to both taxol and vinca alkaloid anti-cancer drugs. Her group is also interested in the design and synthesis of stapled peptides, targeting the disruption of protein-protein interactions of the oncogenic protein MDM2 using this novel class of potential therapeutics, and the development of new methods to visualise drugs within cells and tumours. She collaborates with groups within the Edinburgh Cancer Centre (Ball, Brunton, Carragher, Hupp) and internationally (Fearnhead (NUI Galway, Ireland) to develop potential therapeutic leads.
|Alison Hulme||Principal Investigator and Senior Lecturer|
|Dr Alessio de Simone||Postdoc|
|Will Tipping||PhD student|
|David Georgiev||PhD student|
|Richard Brewster||PhD student|
|Fergus McWhinnie||PhD student|
|Alisia Sim||PhD student|
|Christopher Allan||PhD student|
|Sally Vanden-Hehir||PhD student|
|Kristel Sepp||PhD student|
Bioorthogonal reactions, protein-protein interactions, cancer medicinal chemistry, small molecule imaging.
CuAAC and thiol-ene click reactions, metathesis chemistry, stapled peptides, site-specific protein labelling, affinity chromatography, spectroscopically bioorthogonal Raman labels.